JAMIE CARR: AstraZeneca’s big money from the pandemic
AstraZeneca has kicked Royal Dutch Shell off its perch as the FTSE 100’s most valuable firm
21 May 2020 - 05:00
Big pharma has repeatedly taken it in the neck over the years from commentators who appear outraged that the giants are so cold-hearted as to expect to make a profit from the medicines that they invest billions in to develop.
Clearly the rational answer is that without the chance of profit during the years of a drug’s patent protection, there will be no incentive to invest in R&D, and the production line of medical progress will come to a crashing halt...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.